A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas
Pediatric Blood & Cancer Nov 07, 2017
Kilburn LB, et al. - The intent of the authors was to analyze the progression-free survival (PFS) in children with newly diagnosed diffuse intrinsic pontine gliomas (DIPG), who were given oral capecitabine rapidly disintegrating tablets concurrently with radiation therapy (RT). It was deduced that capecitabine did not improve the outcome for children with newly diagnosed DIPG.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries